April 12, 2023
Meiji Seika Pharma said on April 11 that it has signed an agreement with CSL Seqirus for the distribution and sales of the next-generation mRNA vaccine ARCT-154 against COVID-19 in Japan. The subsidiary of Australia-based CSL currently holds the exclusive...read more